Cassava Sciences Completes Patient Enrollment for Pivotal ...
WEBOct 2, 2023 · A second Phase 3 clinical trial with a target enrollment of approximately 1,100 patients is expected to complete patient enrollment in Q4 2023. Both on-going Phase 3 clinical trials are evaluating the safety and efficacy of oral simufilam in patients with Alzheimer's disease dementia.
Cassava Sciences Announces Completion of an Interim Safety
WEB2 days ago · The DSMB is composed of independent clinical research experts who periodically review interim patient safety data for Cassava Sciences’ on-going Phase 3 trials of simufilam in Alzheimer’s disease.
Cassava Sciences' on-going late stage trials for Alzheimer's ...
WEBCassava Sciences (NASDAQ:SAVA) announced the completion of a third interim safety review of simufilam in on-going late-stage trials Alzheimer’s patients. The scheduled meeting of a Data and ...
Cassava Sciences Simufilam Phase 3 Trials Remain on Track ...
WEBJul 13, 2024 · In a promising development for both the company and those affected by Alzheimer?s disease, Cassava Sciences, Inc. (Nasdaq: SAVA) announced on September 24, 2024, the successful completion of a third interim safety review of its oral treatment, simufilam, in ongoing Phase 3 clinical trials. The review, conducted by an independent Data and Safety Monitoring Board (DSMB), confirmed that both ...
Embattled Alzheimer’s Researcher Is Charged With Fraud
WEBJun 28, 2024 · Hoau-Yan Wang’s work underpinned research into a diagnostic test for Alzheimer’s disease and simufilam, a drug in advanced clinical trials made by Cassava Sciences in Austin, Texas. Ilana...
Cassava Sciences Completes Patient Dosing in a Randomized ...
WEBMay 11, 2023 · SAVA. Cassava Sciences, Inc. The Cognition Maintenance Study (CMS) is a 6-month, Randomized Controlled Trial of Simufilam in Over 125 Patients with Alzheimer’s Disease. Primary Outcome Measures...
PRESS RELEASES - Cassava Sciences, Inc.
WEBMay 8, 2024 · Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of Simufilam $126.3 Million In Total Gross Proceeds from Warrant Distribution. Over 1,900 Patients with Alzheimer’s Disease Are Randomized in Phase 3 Trials of Simufilam.
Cassava Sciences Announces Expansion of Open-Label Extension ...
WEBAUSTIN, Texas, July 30, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) today announced that the Company will extend by up to an additional 36 months each of the open-label...
Cassava Sciences’ Alzheimer’s clinical trials should be halted
WEBOct 17, 2023 · T he Food and Drug Administration should halt Cassava Sciences’ ongoing clinical trials in Alzheimer’s disease. That, and other thoughts on the fallout from the City University of New York ...
Cassava Sciences Stock Rises On Interim Safety Review Of ...
WEB2 days ago · Cassava Sciences, Inc. (NASDAQ: SAVA) shares trading higher following the announcement of a positive interim safety review of its Alzheimer's drug candidate, simufilam. Here's what you need to know.
- Some results have been removed